• Explore /
  • Poster
  • / Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.

Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.

Abstract Poster

Authors

Christopher Hoimes

Christopher J. Hoimes

Duke University, Durham, NC

Christopher J. Hoimes , Yohann Loriot , Jens Bedke , Hiroyuki Nishiyama , Ritesh S. Kataria , Blanca Homet Moreno , Matt D. Galsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04700124

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS588)

DOI

10.1200/JCO.2023.41.6_suppl.TPS588

Abstract #

TPS588

Poster Bd #

P11

Abstract Disclosures

Similar Posters

First Author: Christopher J. Hoimes

First Author: Michael Seth Weinfeld

First Author: Matt D. Galsky

First Author: Arlene O. Siefker-Radtke